New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Viloxazine was historically described as a norepinephrine reuptake inhibitor (NRI). Since NRIs have previously demonstrated efficacy in attention deficit/hyperactivity disorder (ADHD), viloxazine underwent contemporary investigation in the treatment of ADHD. Its clinical and safety profile, however, was found to be distinct from other ADHD medications targeting norepinephrine reuptake. Considering the complexity of neuropsychiatric disorders, understanding the mechanism of action (MoA) is an important differentiating point between viloxazine and other ADHD medications and provides pharmacology-based rationale for physicians prescribing appropriate therapy. METHODS: Viloxazine was evaluated in a series of in vitro binding and functional assays. Its effect on neurotransmitter levels in the brain was evaluated using microdialysis in freely moving rats. RESULTS: receptors, along with predicted high receptor occupancy at clinical doses. In vivo, viloxazine increased extracellular 5-HT levels in the prefrontal cortex (PFC), a brain area implicated in ADHD. Viloxazine also exhibited moderate inhibitory effects on the norepinephrine transporter (NET) in vitro and in vivo, and elicited moderate activity at noradrenergic and dopaminergic systems. CONCLUSION: Viloxazine's ability to increase 5-HT levels in the PFC and its agonistic and antagonistic effects on certain 5-HT receptor subtypes, which were previously shown to suppress hyperlocomotion in animals, indicate that 5-HT modulating activity of viloxazine is an important (if not the predominant) component of its MoA, complemented by moderate NET inhibition. Supported by clinical data, these findings suggest the updated psychopharmacological profile of viloxazine can be best explained by its action as a serotonin norepinephrine modulating agent (SNMA).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Effects of viloxazine on uptake and cellular functional activity in vitro. (A) Dose-dependent inhibition of NET-mediated [3H]-NE uptake (n = 3) measured in rat hypothalamic synaptosomes and [3H]-5-HT uptake (n = 3) measured in HEK293 cells expressing hSERT. (B) Viloxazine activated the response of 5-HT2C (agonist) in a CHO cell-based IP1 HTRF® assay (n = 2). (C) Viloxazine antagonized the activity of 5-HT2B after stimulation with 5-HT in a CHO cell-based IP1 HTRF® assay (n = 2). Data presented as mean ± SEM.](https://figures.cochat.ai/paper-figures/57c3863e5394475e93151e8f7fcfc621/lt-p-gt-new-insights-into-the-mechanism-of-action-of-viloxazine-serotonin-and-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Atomoxetine raises synaptic norepinephrine and dopamine concentrations in the prefrontal cortex [87], while viloxazine modulates serotonin and norepinephrine [88].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [88]
In the citing paper
“Viloxazine, a norepinephrine reuptake inhibitor with additional effects on the serotonin system [73]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The brain on drugs: from reward to addiction
Volkow, N. D., & Morales, M. (2015) · Cell · doi:10.1016/j.cell.2015.07.046 · Cited by 1,306
Emotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070966 · Cited by 1,232
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Cryan, J. F., Valentino, R. J., & Lucki, I. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.008 · Cited by 1,119
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“These results are likely due to the lack of binding affinity of viloxazine at the DAT (KD >100 μM).(18) In addition, viloxazine does not directly interact with the dopaminergic receptors D1 and D2S.”
BackgroundDopamine and drug addiction: the nucleus accumbens shell connection
Di Chiara, G., Bassareo, V., Fenu, S., De Luca, M. A., Spina, L., Cadoni, C., Acquas, E., Carboni, E., Valentini, V., & Lecca, D. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.06.032 · Cited by 935
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Faraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631 · cited 8×
“This is consistent with the longterm cardiac safety profile of viloxazine during its use as an antidepressant in Europe.2,12,62-64 A recently completed randomized clinical trial evaluating the efficacy and safety of extended release viloxazine in the treatment of ADHD, also demonstrated very low rates of cardiovascula…”
ResultInfluentialAmphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 617
Research works printed but not linked: 6
- Foye WO. Pharmacodynamic agents In: Foye’s Principles of Medicinal Chemistry. Lemke TL, Williams DA, Roche VF, and Zito SW, eds. UK: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013: 610.
- Greenwood DT. International vivalan symposium; Animal pharmacology of viloxazine (Vivalan). J Int Med Res. 1975; 3.
- Li D, Kerns EH, edited by. Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs; 2015. ISBN 978-1-118-78835-6 (hardback).
- Paxinos G. The Rat Brain in Stereotaxic Coordinates. 6th ed. Academic Press; 2007.
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Drug Misuse Research Division, Health Research Board. Literature Review on the Relation Between Drug Use, Impaired Driving and Traffic Accidents (CT.97.EP.14). Lisbon: Portugal; 1999.
- Brody T. FDA’s Drug Review Process and the Package Label: Strategies for Writing Successful FDA Submissions. Academic Press; 2018: 441– 511.
Cited by
Evidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Annual Research Review: Perspectives on progress in ADHD science – from characterization to cause
Sonuga‐Barke, E. J. S., Becker, S. P., Bölte, S., Castellanos, F. X., Franke, B., Newcorn, J. H., Nigg, J. T., Rohde, L. A., & Simonoff, E. (2023) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13696 · Cited by 157
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066988 · Cited by 111
“The main action of viloxazine is to increase the brain norepinephrine concentrations, but it is also considered to facilitate the neurotransmission of serotonin, and, to a lesser extent, dopamine (Yu et al., 2020; Findling et al., 2021).”
BackgroundAssociation between ADHD and vision problems. A systematic review and meta-analysis
Bellato, A., Perna, J., Ganapathy, P. S., Solmi, M., Zampieri, A., Cortese, S., & Faraone, S. V. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01699-0 · Cited by 87
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H. (2021) · CNS Drugs · doi:10.1007/s40263-021-00825-w · Cited by 55
“A recent study found viloxazine to demonstrate weak competitive inhibition (< 25%) at histamine receptors H1 and H2 and muscarinic receptors M1–4, and notably low affinity towards monoamine oxidase A [15].”
BackgroundSelf-citationNasser, A., Liranso, T., Adewole, T., Fry, N., Hull, J. T., Chowdhry, F., Busse, G. D., Melyan, Z., Cutler, A. J., Findling, R. L., et al. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.01.027 · Cited by 55
Self-citationNasser, A. F., Hull, J. T., Chaturvedi, S. A., Liranso, T., Odebo, O., Kosheleff, A. R., Fry, N., Cutler, A. J., Rubin, J. S., Schwabe, S., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00938-w · Cited by 60
“The therapeutic effects of this novel nonstimulant medication are thought to be owing to its action as a norepinephrine reuptake inhibitor; however, contemporary preclinical studies indicate that it may also act on serotonergic signaling in the brain, though the translational effect in humans remains to be fully eluci…”
BackgroundSelf-citationManter, M. A., Birtwell, K. B., Bath, J., Friedman, N. D. B., Keary, C. J., Neumeyer, A. M., Palumbo, M. L., Thom, R. P., Stonestreet, E., Brooks, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-024-03814-0 · Cited by 51
“Atomoxetine raises synaptic norepinephrine and dopamine concentrations in the pre-frontal cortex [87], while viloxazine modulates serotonin and norepinephrine [88].”
Nasser, A. F., Liranso, T., Adewole, T., Fry, N., Hull, J. T., Busse, G. D., Chowdhry, F. A., Cutler, A. J., Jones, N. J., Findling, R. L., et al. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001404 · Cited by 49
Self-citationKhoodoruth, M. A. S., Ouanes, S., & Khan, Y. S. (2022) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2022.104275 · Cited by 39
Nasser, A. F., Liranso, T., Adewole, T., Fry, N., Hull, J. T., Chowdhry, F. A., Busse, G. D., Melyan, Z., Cutler, A. J., Findling, R. L., et al. (2021) · PubMed · Cited by 44
Self-citationCortese, S., Newcorn, J. H., & Coghill, D. (2021) · CNS Drugs · doi:10.1007/s40263-021-00848-3 · Cited by 38
“Viloxazine is an unscheduled selective noradrenaline reuptake inhibitor with antagonistic activity at 5-HT2B and agonistic activity at 5-HT2C receptors [19].”
BackgroundEpilepsy and Attention Deficit Hyperactivity Disorder: Connection, Chance, and Challenges
Fan, H., Chiang, K.-L., Chang, K., Chen, C., & Tsai, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065270 · Cited by 45
Adult attention deficit hyperactivity disorder: a comprehensive review
Williams, O. C. A., Prasad, S., McCrary, A., Jordan, E., Sachdeva, V., Deva, S., Kumar, H., Mehta, J., Neupane, P., & Gupta, A. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000631 · Cited by 60
“In comparison to medications used for depression, the drug viloxazine seems to have anti-epileptic properties at low doses([63]).”
Faraone, S. V., Goméni, R., Hull, J. T., Busse, G. D., Melyan, Z., O’Neal, W., Rubin, J. S., & Nasser, A. F. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2020.113664 · Cited by 34
“SPN-812 (viloxazine extended-release) is an investigational medication for ADHD that has demonstrated activity at norepinephrine transporter and several serotonin receptors (Yu et al., 2020).”
BackgroundNeurobiology of Attention Deficit Hyperactivity Disorder
Faraone, S. V., & Radonjić, N. V. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_33-1 · Cited by 35
Viloxazine: Pediatric First Approval
Lamb, Y. N. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00453-3 · Cited by 29
Faison, S. L., Fry, N., Adewole, T., Odebo, O., Wang, Z., Maletic, V., & Nasser, A. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001361 · Cited by 28
“SPN-812 (viloxazine extended-release) has a novel, multimodal mechanism of action, with demonstrated activity at serotonin receptors and the norepinephrine transporter.(20) The original, immediate-release viloxazine formulation was approved in Europe as an antidepressant in 1974 and marketed for 28 years, before being…”
BackgroundSelf-citationViloxazine in the Treatment of Attention Deficit Hyperactivity Disorder
Edinoff, A. N., Akuly, H. A., Wagner, J. H., Boudreaux, M. A., Kaplan, L. A., Yusuf, S., Neuchat, E. E., Cornett, E. M., Boyer, A. G., Kaye, A. M., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.789982 · Cited by 30
Nonstimulant Treatments for ADHD
Newcorn, J. H., Krone, B., & Dittmann, R. W. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.03.005 · Cited by 29
Cutler, A. J., Mattingly, G. W., Jain, R., & O’Neal, W. (2020) · CNS Spectrums · doi:10.1017/s1092852920001984 · Cited by 26
Faison, S. L., Fry, N., Adewole, T., Odebo, O., Schwabe, S., Wang, Z., Maletic, V., & Nasser, A. F. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00992-6 · Cited by 24
Self-citationMontano, C. B., Jackson, W., Vanacore, D., & Weisler, R. H. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2189868 · Cited by 31
“A meta-analysis of 7 RCTs demonstrated comparable efficacy between bupropion and the SSRIs fluoxetine, sertraline, and paroxetine [41].”
BackgroundInfluentialExtended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
Price, M. Z., & Price, R. L. (2023) · CNS Drugs · doi:10.1007/s40263-023-01023-6 · Cited by 23
Nasser, A. F., Goméni, R., Wang, Z., Kosheleff, A. R., Xie, L., Adeojo, L., & Schwabe, S. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1940 · Cited by 22
“These plots included: (1) the observed concentrations versus individual and population-predicted concentrations, (2) the absolute individual weighed residuals versus individual predictions, and (3) the conditional weighted residuals versus time.”
BackgroundMethodSelf-citationNasser, A. F., Kosheleff, A. R., Hull, J. T., Liranso, T., Qin, P., Busse, G. D., O’Neal, W., Fava, M., Faraone, S. V., & Rubin, J. S. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0148 · Cited by 23
“All four trials were randomized, double-blind, placebo-controlled, multicenter, three-arm, parallel-group studies evaluating efficacy and safety of SPN-812, a novel agent with demonstrated activity at serotonin receptors and the norepinephrine transporter (Yu et al. 2020), in pediatric patients with ADHD.”
BackgroundA year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02250-2 · Cited by 22
“It has moderate norepinephrine reuptake inhibitor, serotonin 5-HT2B receptor antagonism, and 5-HT2C receptor agonism properties in vitro that in combination lead to increased noradrenaline, serotonin, and dopamine levels in the prefrontal cortex in a preclinical model (Yu et al. 2020).”
BackgroundEvaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults
Nasser, A. F., Faison, S. L., Liranso, T., Adewole, T., Busse, G. D., Fava, M., Kleiman, R., & Schwabe, S. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13395 · Cited by 20
Self-citationBaweja, R. K., Faraone, S. V., Childress, A. C., Weiss, M. D., Loo, S. K., Wilens, T. E., & Waxmonsky, J. G. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0022 · Cited by 18
“The IR formulation was marketed as an antidepressant in Europe (Findling et al., 2021, Yu, 2020, Yu et al., 2020).”
Faraone, S. V., Goméni, R., Hull, J. T., Busse, G. D., Melyan, Z., Rubin, J. S., & Nasser, A. F. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00470-2 · Cited by 20
Wiggs, K. K., Froehlich, T. E., & Becker, S. P. (2023) · CNS Drugs · doi:10.1007/s40263-023-00999-5 · Cited by 16
“Viloxazine, a norepinephrine reuptake inhibitor with additional effects on the serotonin system [73] has long been used in Europe to treat depression [74].”
MethodWang, Z., Kosheleff, A. R., Adeojo, L., Odebo, O., Adewole, T., Qin, P., Maletic, V., Schwabe, S., & Nasser, A. F. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.948 · Cited by 17
Self-citationSingh, A. D., Balasundaram, M. K., & Singh, A. (2022) · Journal of Central Nervous System Disease · doi:10.1177/11795735221092522 · Cited by 18
“Viloxazine increases serotonin and norepinephrine levels in the prefrontal cortex and causes a minimal increase of dopamine levels in the nucleus accumbens makes it a novel drug for ADHD with the least abuse potential.(13) The median time taken to reach the maximum concentration (Tmax) for viloxazine ranges between 6…”
Neuron-Specific Enolase (NSE) as a Biomarker for Autistic Spectrum Disease (ASD)
Stancioiu, F., Bogdan, R. D., & Dumitrescu, R. (2023) · Life · doi:10.3390/life13081736 · Cited by 22
“Viloxazine increases activity in the prefrontal cortex, possibly via differential actions on 5-HT receptors: antagonistic on 5-HT2B and agonistic on 5-HT2C receptors, and also acts on the norepinephrine transporter [62],— causing an important modulation of the cortico-basal tracts involved in the cortical control of t…”
BackgroundAn updated review on morpholine derivatives with their pharmacological actions
Meher, C. P., Purohit, D., Kumar, A., Singh, R., & Dubey, A. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns3.5983 · Cited by 18
“(RS)-2-[(2-ethoxyphenoxy)-methyl]-morpholine Mechanism of action: [73]”
New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development
Heal, D. J., Gosden, J., & Smith, S. L. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_332 · Cited by 17
García‐Olivares, J., Yegla, B., Bymaster, F. P., Earnest, J., Koch, J., Yu, C., & Rubin, J. S. (2024) · Journal of Experimental Pharmacology · doi:10.2147/jep.s433524 · Cited by 14
“This supports the interpretation that viloxazine increases NE (and DA) in the PFC by inhibiting NET, 4 in line with previous observations of its moderate inhibitory activity of NET (IC 50 =0.3 µM) in rat synaptosome preparations, 6 and characterization as a NRI.”
BackgroundResultInfluentialSelf-citationHuang, X., Hu, J., Peng, H., & Cheng, H. W. (2022) · Nutrients · doi:10.3390/nu14030661 · Cited by 13
“The NE reuptake inhibitor, viloxazine, with a second function of inhibiting the activities of the DA receptors and transporters, increases the availability of DA and NE [76] and reduces symptoms of impulsivity and inattention in ADHD, which is directly related to bullying behaviors in males [77].”
BackgroundCurrent nonstimulant medications for adults with attention-deficit/hyperactivity disorder
Brancati, G. E., Magnesa, A., Acierno, D., Carli, M., Rosa, U. D., Froli, A., Gemignani, S., Ventura, L., Weiss, F., & Perugi, G. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2370346 · Cited by 21
“Specifically, increased release of serotonin, particularly in the prefrontal cortex, may result from the inhibition of GABA interneurons through antagonistic action on 5-HT 2B receptors [152].”
Early Life Stress and Gut Microbiome Dysbiosis: A Narrative Review
Borrego-Ruiz, A., & Borrego, J. J. (2025) · Stresses · doi:10.3390/stresses5020038 · Cited by 13
Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder
Robinson, C. L., Parker, K., Kataria, S., Downs, E., Supra, R., Kaye, A. D., Viswanath, O., & Urits, I. (2022) · Health Psychology Research · doi:10.52965/001c.38360 · Cited by 16
Nasser, A. F., Kosheleff, A. R., Hull, J. T., Liranso, T., Qin, P., Busse, G. D., Fava, M., Maletic, V., Rubin, J. S., & López, F. A. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14330 · Cited by 13
Self-citationFaraone, S. V., Goméni, R., Hull, J. T., Busse, G. D., Melyan, Z., Rubin, J. S., & Nasser, A. F. (2021) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-021-01877-5 · Cited by 9
“Preclinical studies have also demonstrated activity in the serotonergic system in the prefrontal cortex, although the translation of these observations into humans remains to be elucidated [17].”
BackgroundProlonged STAT1 signaling in neurons causes hyperactive behavior
Clark, D. N., Brown, S. V., Xu, L., Lee, R., Ragusa, J. V., Xu, Z., Milner, J. D., & Filiano, A. J. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.11.018 · Cited by 9
Yacoub, M., Smith, S., Abbas, B., Iqbal, F., Jazieh, C., Shaer, N. S. H. A., Luk, C., & Syed, N. I. (2025) · Cells · doi:10.3390/cells14171367 · Cited by 20
“It has also been shown that viloxazine antagonizes 5HT2B receptors on GABA interneurons to increase the availability of 5-HT in the prefrontal cortex [225].”
An updated safety review of the current drugs for managing ADHD in children
Ryst, E., & Childress, A. C. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2271392 · Cited by 9
“…to work primarily through inhibition of norepinephrine re-uptake; however, because it also appears to increase serotonin by acting as an agonist at the 5-HT2 C receptor and as an antagonist at the 5-HT2 B receptor, it may be best explained as a serotonin-norepinephrine modulating agent [100–102].”
BackgroundThe management of attention-deficit hyperactivity disorder in children: updated 2022
Chigome, A., Meyer, J. C., & Schellack, N. (2022) · South African General Practitioner · doi:10.36303/sagp.2022.3.4.0140 · Cited by 9
Faraone, S. V., Goméni, R., Hull, J. T., Busse, G. D., Lujan, B., Rubin, J. S., & Nasser, A. F. (2023) · Brain and Behavior · doi:10.1002/brb3.2910 · Cited by 7
“Viloxazine ER is a norepinephrine reuptake inhibitor; however, contemporary preclinical studies indicate that it also acts on serotonergic signaling in the brain, but the translational effect in humans remains to be fully elucidated (Yu et al., 2020).”
BackgroundChildress, A. C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2358987 · Cited by 8
“VLX-ER is a NE reuptake inhibitor with serotonin (5HT) modulating effects [73].”
BackgroundSolomon, M. B., Yegla, B., Newcorn, J. H., Maletic, V., Rubin, J. S., & Robbins, T. W. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01473-4 · Cited by 11
“Atomoxetine has moderate binding at SERT [412], while viloxazine has negligible binding affinity for SERT [413] but unique effects at 5-HT receptors that are not observed with atomoxetine and may theoretically contribute to its mechanism of action.”
InfluentialSelf-citationRaible, H., & D’Souza, M. S. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231163252 · Cited by 11
“14 A preclinical study reported an increase in dopamine and norepinephrine levels in the PFC after viloxazine administration.”
BackgroundInfluentialA clinician’s guide for navigating the world of attention deficit hyperactivity disorder medications
Mattingly, G. W., & Young, J. L. (2021) · CNS Spectrums · doi:10.1017/s1092852921000146 · Cited by 6
Mather, K., & Condren, M. E. (2022) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-27.5.409 · Cited by 8
TO MARKET, TO MARKET–2021: SMALL MOLECULES
Araujo, E., Bell, I. M., Burckle, A. J., Koester, D. C., Manning, J. R., Caldwell, R. D., Castanedo, G. M., Green, S. A., Zeng, M., Debien, L., et al. (2022) · Medicinal chemistry reviews · doi:10.1021/mc-2022-vol57.ch24 · Cited by 7
Faraone, S. V., Ward, C. L., Boucher, M., Elbekai, R. H., & Brunner, E. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2552324 · Cited by 10
“Meanwhile, the NRI viloxazine increased serotonin levels in the PFC and had antagonistic and agonistic effects, respectively, on 5-HT 2B and 5-HT 2C receptor subtypes previously shown to suppress hyperlocomotion in animals (medium grade, nonclinical) [109].”
Tan, X., Xu, Y., Wang, S., Li, J., Hu, C., Chen, Z., Cheng, Q., & Wang, Z. (2023) · Brain Sciences · doi:10.3390/brainsci13121627 · Cited by 7
“As a selective 5-HT 2B receptor antagonist and 5-HT2C receptor agonist, SPN-812 modulates serotonergic activity and moderately inhibits norepinephrine transporter (NET), thus blocking the reuptake of norepinephrine [19].”
BackgroundWang, Z., Liranso, T., Maldonado-Cruz, Z., Kosheleff, A. R., & Nasser, A. F. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01356-0 · Cited by 5
“Additionally, it shows functional activity as a 5HT2C partial agonist and 5HT7 antagonist in preclinical research [4].”
BackgroundThe role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium
Ilipilla, G. S., & Arnold, L. E. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2369197 · Cited by 8
“This finding is consistent with the low rate of cardiac effects clinically [31].”
ResultChildress, A. C., Sottile, R., & Khanbijian, S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2265068 · Cited by 5
“Viloxazine increases serotonin (5-HT) levels in the prefrontal cortex [27].”
BackgroundAlsoqih, N. S., Elmorsy, E. A., Abu‐Khudir, R., Saber, S., Keshk, N., Elnaghy, F., Hamad, R. S., El-kott, A. F., Negm, S., AlShehri, M. A., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202501829rr · Cited by 6
“This classification supports it as an SNMA, with serotonin contributing substantially to its mechanism of action [95].”
InfluentialAttention Deficit Hyperactivity Disorder
Marco, P., Maddalena, M., Bertella, S., Gatti, E., & Nobile, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00164-x · Cited by 5
Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication
Balasundaram, M. K., & Singh, A. D. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00892-z · Cited by 4
“Viloxazine causes a minimal increase in dopamine levels in the nucleus accumbens, making it a novel drug for ADHD with the least abuse potential [15].”
Childress, A. C., & Burton, S. M. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2103406 · Cited by 5
“a serotonin norepinephrine modulating agent [33].”
BackgroundInfluentialHaddad, H. W., Hankey, P. B., Ko, J., Eswani, Z., Bhatti, P., Edinoff, A. N., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.37018 · Cited by 8
Childress, A. C., Cutler, A. J., Adler, L. A., Fry, N., Asubonteng, K. O., Maldonado-Cruz, Z., Formella, A. E., & Rubin, J. S. (2024) · CNS Drugs · doi:10.1007/s40263-024-01120-0 · Cited by 8
“Still, viloxazine shows notable pharmacologic differences from atomoxetine (Strattera ® , Eli Lilly and Company), a potent NE reuptake inhibitor [18], including more moderate affinity for the NE transporter and potentially relevant activity at certain serotonin (5-HT) receptors [19].”
InfluentialNewly FDA-approved psychotropic agents-a recap
Naguy, A., Solanki, A. P. S., & Alamiri, B. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102786 · Cited by 4
A review on ADHD disorder, diagnosis and therapeutic approach in children and adolescents
Kumar, G., Sharma, B., Tiwari, R. K., Kumar, R., & Singh, M. K. (2024) · Brain-Apparatus Communication A Journal of Bacomics · doi:10.1080/27706710.2024.2400070 · Cited by 4
Xu, X.-P., Wang, W., Wan, S., & Xiao, C. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i26.9219 · Cited by 3
Adrenoceptors: A Focus on Psychiatric Disorders and Their Treatments
Stanford, S. C., & Heal, D. J. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_675 · Cited by 4
Nasser, A. F., Goméni, R., Wang, Z., Hull, J. T., Busse, G. D., Melyan, Z., Fava, M., O’Neal, W., & Rubin, J. S. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15412 · Cited by 2
Gonda, X., Döme, P., Balogh, L., Baradits, M., & Réthelyi, J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.108997 · Cited by 3
The Neurobiology of Prader-Willi Syndrome
Singh, D. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108886727.015 · Cited by 3
ADHD-A Clinician’s Bird’s Eye View of Current Status and New Vistas!
Naguy, A., PRIDMORE, S. A., Alwetayan, S., Elsori, D. H., & Alamiri, B. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4461 · Cited by 5
Viloxazine: A New Non-Stimulant Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD)
Wilanowska, W., Gregułą, A., Stachyrak, K., Mika, D., Kłos, A., Turek, K., Lambach, M., Pawlicki, M., Mazurek, A., & Mazur, B. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.58.006 · Cited by 2
Maletic, V., Mattingly, G. W., & Earnest, J. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2327533 · Cited by 2
“Changes in neurotransmitter levels across different parts of the brain were characterized using microdialysis in freely moving rats [76].”
BackgroundMethodInfluentialSelf-citationChapter 60. Treatment of Child and Adolescent Disorders
Wagner, K., & Pliszka, S. R. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as60 · Cited by 1
Diagnosis and Management of Comorbid ADHD in Patients with Substance Use Disorders
Busch, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-72219-6_50 · Cited by 1
Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults
Syed, Y. Y. (2025) · CNS Drugs · doi:10.1007/s40263-025-01227-y · Cited by 4
“Viloxazine is over 100 times more selective for NET than for the 5-HT transporter (dissociation constant K D ratio ≈110), and has negligible affinity for the dopamine and 5-HT transporters [20].”
García‐Olivares, J., Yegla, B., Koch, J., Yu, C., & Rubin, J. S. (2026) · Drugs in R&D · doi:10.1007/s40268-026-00543-y · Cited by 1
“A [ 3 H]NE uptake assay evaluating the inhibitory effect of viloxazine on the human isoform of NET expressed in CHO cells showed high inhibition of NET (IC 50 = 0.370 µM; Table 2), which is consistent with a previously reported IC 50 using a rat hypothalamic synaptosome preparation (0.26 µM) [9].”
InfluentialSelf-citationLópez-Cruz, M. J., & Arronte-Rosales, A. (2023) · Casos y Revisiones de Salud · doi:10.22201/fesz.26831422e.2023.5.2.5 · Cited by 1
Hafeez, S., Saquib, J., & Qureshi, N. E. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102948 · Cited by 1
Kameg, B. (2022) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20220610-04
Khanifah, F., Sari, E. P., & Nugraha, G. (2024) · Journal Pharmasci (Journal of Pharmacy and Science) · doi:10.53342/pharmasci.v9i1.412
Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
Strawn, J. R., & Stahl, S. M. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009049719.015
Stahl, S. M. (2024) · Prescriber's Guide · doi:10.1017/9781009464772.150
Neurobiology of Attention Deficit Hyperactivity Disorder
Faraone, S. V., & Radonjić, N. V. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_33 · Cited by 2
(2025) · Wiley eBooks · doi:10.1002/9781118941430.refs
Findling, R. L., Katic, A., Liebowitz, M. R., Waxmonsky, J. G., Fry, N., Qin, P., Yarullina, I., Maldonado-Cruz, Z., Lieberman, V. R., & Rubin, J. S. (2025) · CNS Drugs · doi:10.1007/s40263-025-01209-0 · Cited by 3
“At therapeutic doses, viloxazine ER also has relevant activity at serotonin receptors as a 5-HT2c partial agonist, and 5-HT2b and 5HT-7 antagonist [21, 22].”
Animal models of attention-deficit/hyperactivity disorder: Diversity and validity
Nehme, S. B. S., Sánchez‐Sarasúa, S., Medrano, M., Bouchatta, O., Bitar, T., Alameddine, A., Galineau, L., Brunault, P., Kerekes, N., Sánchez‐Pérez, A. M., et al. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100108
ADHD treatments move beyond stimulants
Jones, N. (2026) · Nature · doi:10.1038/d41586-026-00095-w · Cited by 1
Mansour, G. K., Sayed, S. B. H., Al‐Badri, S. G., Abdalla, M. G. A., & Abo‐elnour, D. E. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70839
“It was historically classified as a selective NRI based on animal and human studies [2].”
InfluentialThe Evolving Pharmacological Landscape for Paediatric and Adult ADHD
Veronesi, G. F., Tarantino, F., Pirolo, D., & Cortese, S. (2026) · CNS Drugs · doi:10.1007/s40263-026-01299-4
“Viloxazine, the lat-est medication approved by the FDA for ADHD (in 2021 for children and in 2022 for adults), is a non-stimulant that acts primarily through reuptake inhibition of norepinephrine and serotonin [13].”
García‐Olivares, J., Yegla, B., Ridler, K., Rizzo, G., Fan, Z., Amenta, A. L., Morén, A. F., Halldin, C., Stepanov, V., Koch, J., et al. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag034
“10 , 14 These in vitro findings need to be bolstered by in vivo studies, but if viloxazine binds to 5-HT 2C , 5-HT 2B , and/or 5-HT 7 in vivo, it is possible this action may play a role in viloxazine’s therapeutic activity.”
InfluentialSelf-citationReassessing ADHD Management: Integrating Gut Microbiome Insights and Herbal Nutritional Strategies
Elkalla, W. S., Salah, A. N., Mahmoud, N. A., AbdelRazek, M. M. M., Kotb, S. S., Elshami, N. H., AlFarsi, K., Waseem, A. M., Bogari, H. A., Malatani, R. T., et al. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00712-0 · Cited by 1
Wang, Z., Adewole, T., Adeojo, L., Qin, P., Schwabe, S., & Nasser, A. F. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01580-w
“The role of these pharmacodynamic effects in mediating therapeutic effects is unclear, and translational implications in humans remain to be fully elucidated [3].”
Self-citationLC-MS/MS-Based Selective Degradant Separation and Mass Spectral Characterization of Viloxazine
Shivaprasad, Adithyamathur, & Dr.Ratnasre (2020) · Journal of Science and Technology · doi:10.46243/jst.2020.v5.i04.pp215-222
El Masri, S., Kowalczyk, O. S., Criaud, M., Lukito, S., Mazibuko, N., Salazar de Pablo, G., Perez-Rodriguez, V., Makos, O., Lam, S.-L., Westwood, S., et al. (2026) · doi:10.64898/2026.10.01.26364506
Metadata
- Authors
- Yu, C., Garcia-Olivares, J., Candler, S., Schwabe, S., & Maletic, V.
- Affiliations
- Supernus Pharmaceuticals (United States) (US)
- University of South Carolina (US)
- Venue
- Journal of Experimental Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2020-08
- Volume
- Volume 12
- Pages
- 285-300
- ISSN
- 1179-1454 (ISSN-L)
- PMC
- PMC7473988
- OpenAlex
- W3080466884
- Cited by
- 96
- References
- 76
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 16 · 2023: 15 · 2022: 22 · 2021: 20 · 2020: 4
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Experimental Pharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Supernus Pharmaceuticals
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- viloxazine, mechanism of action, serotonin transporter, norepinephrine transporter, serotonin receptor antagonism, attention deficit hyperactivity disorder, prefrontal cortex, extracellular serotonin, noradrenergic system, dopaminergic system, norepinephrine reuptake inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.